Bixiye
bc-mhcp-pharmprogpolicynotifctn-final-eff-5.1.23.pdf
Natiijooyinka Raadinta
Soo bandhiga 1701 - 1710 ee natiijooyinka 4139
Bixiye
QP27-23 Commercial and MHCP Pharmacy Benefit Exclusion for Syfovre™
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Bixiye
QP28-23 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective June 1, 2023
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Bixiye
QP29-23 Blue Cross Preferred Genetic Laboratory Program
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Bixiye
QP30-23 MHCP Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective May 1, 2023
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Bixiye
QP31-23 Commercial Pharmacy Benefit Exclusion for Fluticasone-Salmeterol
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Bixiye
QP32-23 Review and Update NPI Information
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Bixiye
QP33-23 Provider Survey: Training & Development Focusing on Equity in Health Care
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023
Bixiye
QP34-23 Update for New to Market Medical Drugs: Tofersen
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 12, 2023